These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 28180952)

  • 1. Endothelial dysfunction during long-term follow-up in children with STEC hemolytic-uremic syndrome.
    Kreuzer M; Sollmann L; Ruben S; Leifheit-Nestler M; Fischer DC; Pape L; Haffner D
    Pediatr Nephrol; 2017 Jun; 32(6):1005-1011. PubMed ID: 28180952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome 10 years after Shiga toxin-producing E. coli (STEC)-associated hemolytic uremic syndrome: importance of long-term follow-up.
    Rosales A; Kuppelwieser S; Giner T; Hofer J; Riedl Khursigara M; Orth-Höller D; Borena W; Cortina G; Jungraithmayr T; Würzner R;
    Pediatr Nephrol; 2024 Aug; 39(8):2459-2465. PubMed ID: 38589699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of diarrhea-associated hemolytic uremic syndrome is poorly related to markers of kidney injury at 1-year follow-up in a population-based cohort.
    Monet-Didailler C; Godron-Dubrasquet A; Madden I; Delmas Y; Llanas B; Harambat J
    Pediatr Nephrol; 2019 Apr; 34(4):657-662. PubMed ID: 30368614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection.
    Bruyand M; Mariani-Kurkdjian P; Gouali M; de Valk H; King LA; Le Hello S; Bonacorsi S; Loirat C
    Med Mal Infect; 2018 May; 48(3):167-174. PubMed ID: 29054297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).
    Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS
    Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiopoietin-1 and -2 as markers for disease severity in hemolytic uremic syndrome induced by enterohemorrhagic Escherichia coli.
    Shimizu M; Inoue N; Kuroda M; Mizuta M; Sugimoto N; Kaneda H; Ohta K; Yachie A
    Clin Exp Nephrol; 2017 Feb; 21(1):76-82. PubMed ID: 26945868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome.
    Ylinen E; Salmenlinna S; Halkilahti J; Jahnukainen T; Korhonen L; Virkkala T; Rimhanen-Finne R; Nuutinen M; Kataja J; Arikoski P; Linkosalo L; Bai X; Matussek A; Jalanko H; Saxén H
    Pediatr Nephrol; 2020 Sep; 35(9):1749-1759. PubMed ID: 32323005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab.
    Ağbaş A; Göknar N; Akıncı N; Yıldırım ZY; Taşdemir M; Benzer M; Gökçe İ; Candan C; Küçük N; Uzuner S; Özçelik G; Demirkol D; Sever L; Çalışkan S
    Pediatr Nephrol; 2018 Dec; 33(12):2371-2381. PubMed ID: 30159625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008.
    Jenssen GR; Vold L; Hovland E; Bangstad HJ; Nygård K; Bjerre A
    BMC Infect Dis; 2016 Jun; 16():285. PubMed ID: 27297224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Post-diarrheal haemolytic uremic syndrome: when shall we consider it? Which follow-up?].
    Bertholet-Thomas A; Ranchin B; King LA; Bacchetta J; Belot A; Gillet Y; Collardeau-Frachon S; Cochat P
    Arch Pediatr; 2011 Jul; 18(7):823-30. PubMed ID: 21571510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS).
    Khalid M; Andreoli S
    Pediatr Nephrol; 2019 Dec; 34(12):2495-2507. PubMed ID: 30382336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.
    Percheron L; Gramada R; Tellier S; Salomon R; Harambat J; Llanas B; Fila M; Allain-Launay E; Lapeyraque AL; Leroy V; Adra AL; Bérard E; Bourdat-Michel G; Chehade H; Eckart P; Merieau E; Piètrement C; Sellier-Leclerc AL; Frémeaux-Bacchi V; Dimeglio C; Garnier A
    Pediatr Nephrol; 2018 Aug; 33(8):1385-1394. PubMed ID: 29572749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of angiopoietin 1 and 2 in Escherichia coli O157:H7 infection and the hemolytic-uremic syndrome.
    Page AV; Tarr PI; Watkins SL; Rajwans N; Petruzziello-Pellegrini TN; Marsden PA; Kain KC; Liles WC
    J Infect Dis; 2013 Sep; 208(6):929-33. PubMed ID: 23801605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) who suffered from multiple organ involvement in the early stage.
    Luna M; Kamariski M; Principi I; Bocanegra V; Vallés PG
    Pediatr Nephrol; 2021 Jun; 36(6):1499-1509. PubMed ID: 33205220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study.
    Monet-Didailler C; Chevallier A; Godron-Dubrasquet A; Allard L; Delmas Y; Contin-Bordes C; Brissaud O; Llanas B; Harambat J
    Nephrol Dial Transplant; 2020 Dec; 35(12):2147-2153. PubMed ID: 31411695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum neutrophil gelatinase-associated lipocalin (NGAL) in patients with Shiga toxin mediated haemolytic uraemic syndrome (STEC-HUS).
    Lukasz A; Beneke J; Menne J; Vetter F; Schmidt BM; Schiffer M; Haller H; Kümpers P; Kielstein JT
    Thromb Haemost; 2014 Feb; 111(2):365-72. PubMed ID: 24172823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble plasma VE-cadherin concentrations are elevated in patients with STEC infection and haemolytic uraemic syndrome: a case-control study.
    Doulgere J; Otto B; Nassour M; Wolters-Eisfeld G; Rohde H; Magnus T; Wagener C; Streichert T
    BMJ Open; 2015 Mar; 5(3):e005659. PubMed ID: 25757942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4.
    Loos S; Aulbert W; Hoppe B; Ahlenstiel-Grunow T; Kranz B; Wahl C; Staude H; Humberg A; Benz K; Krause M; Pohl M; Liebau MC; Schild R; Lemke J; Beringer O; Müller D; Härtel C; Wigger M; Vester U; Konrad M; Haffner D; Pape L; Oh J; Kemper MJ
    Clin Infect Dis; 2017 Jun; 64(12):1637-1643. PubMed ID: 28329394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemolytic Uremic Syndrome-Induced Acute Kidney Injury Treated via Immunomodulation with the Selective Cytopheretic Device.
    Hambrick HR; Short K; Askenazi D; Krallman K; Pino C; Yessayan L; Westover A; Humes HD; Goldstein SL
    Blood Purif; 2023; 52(9-10):812-820. PubMed ID: 37607519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An epidemiologic surveillance of Shiga-like toxin-producing Escherichia coli infection in Argentinean children: risk factors and serum Shiga-like toxin 2 values.
    López EL; Contrini MM; Glatstein E; Ayala SG; Santoro R; Ezcurra G; Teplitz E; Matsumoto Y; Sato H; Sakai K; Katsuura Y; Hoshide S; Morita T; Harning R; Brookman S
    Pediatr Infect Dis J; 2012 Jan; 31(1):20-4. PubMed ID: 21829137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.